AngioDynamics (NASDAQ:ANGO) Updates FY 2026 Earnings Guidance

AngioDynamics (NASDAQ:ANGO) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of -0.330–0.230 for the period, compared to the consensus earnings per share estimate of -0.310. The company issued revenue guidance of $308.0 million-$313.0 million, compared to the consensus revenue estimate of $306.9 million.

AngioDynamics Stock Performance

NASDAQ:ANGO opened at $11.64 on Friday. AngioDynamics has a fifty-two week low of $5.83 and a fifty-two week high of $13.50. The company has a market cap of $478.17 million, a price-to-earnings ratio of -14.92 and a beta of 0.78. The stock has a fifty day moving average price of $9.94 and a 200-day moving average price of $9.76.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings results on Thursday, October 2nd. The medical instruments supplier reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02. AngioDynamics had a negative return on equity of 3.16% and a negative net margin of 10.67%.The company had revenue of $75.71 million during the quarter, compared to analysts’ expectations of $72.69 million. During the same quarter in the previous year, the firm earned ($0.11) EPS. AngioDynamics’s revenue was up 12.1% on a year-over-year basis. AngioDynamics has set its FY 2026 guidance at -0.330–0.230 EPS. Research analysts predict that AngioDynamics will post -0.37 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ANGO has been the topic of several research analyst reports. HC Wainwright restated a “buy” rating and set a $16.00 target price on shares of AngioDynamics in a research report on Wednesday, July 16th. Lake Street Capital started coverage on AngioDynamics in a research note on Wednesday, July 16th. They issued a “buy” rating and a $24.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a research report on Saturday, September 27th. Wall Street Zen downgraded AngioDynamics from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Canaccord Genuity Group raised their target price on AngioDynamics from $17.00 to $18.00 and gave the stock a “buy” rating in a research report on Friday. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.33.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Goldman Sachs Group Inc. increased its holdings in AngioDynamics by 9.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 259,226 shares of the medical instruments supplier’s stock valued at $2,434,000 after purchasing an additional 22,658 shares during the period. Invesco Ltd. lifted its position in AngioDynamics by 2.2% in the 2nd quarter. Invesco Ltd. now owns 122,596 shares of the medical instruments supplier’s stock valued at $1,216,000 after acquiring an additional 2,667 shares in the last quarter. American Century Companies Inc. lifted its position in AngioDynamics by 15.8% in the 2nd quarter. American Century Companies Inc. now owns 96,808 shares of the medical instruments supplier’s stock valued at $960,000 after acquiring an additional 13,217 shares in the last quarter. Squarepoint Ops LLC lifted its position in AngioDynamics by 28.3% in the 2nd quarter. Squarepoint Ops LLC now owns 85,696 shares of the medical instruments supplier’s stock valued at $850,000 after acquiring an additional 18,879 shares in the last quarter. Finally, Jane Street Group LLC lifted its position in AngioDynamics by 46.0% in the 2nd quarter. Jane Street Group LLC now owns 68,329 shares of the medical instruments supplier’s stock valued at $678,000 after acquiring an additional 21,526 shares in the last quarter. Hedge funds and other institutional investors own 89.43% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.